Real-world data show potential of Cosela to reduce myelosuppression in ES-SCLC treated with chemo

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A retrospective, observational study sponsored by G1 Therapeutics described the burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer. The study also described patient outcomes from 21 patients receiving Cosela (trilaciclib) prior to chemotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login